Section VII. Trends and perspectives
作者： Bernard Gaudilliere , Patrick Berna
DOI: 10.1016/S0065-7743(00)35031-X
关键词:
摘要: Publisher Summary This chapter discusses new therapeutic entities introduced worldwide in the markets 1999. Among active marketed for human use, biological (NBEs) that were biotechnology-based drugs (mainly recombinant proteins) represented a significant proportion. They innovative approaches to treatment of several important diseases. A total 35 into their first 1999, making it more productive than previous years 1995–1998. The launch considered as priority drugs, which gains over existing patients and medical community ranked particularly high. With 15 launches US maintained top rank terms introductions, followed by Europe Japan with 8 7 respectively. launches, anti-infectives one most groups. An overview different is provided chapter, including abacavir sulfate (antiviral), alitretinoin (anticancer), amprenavir arglabin celecoxib (antiarthritic), cetrorelix, CHF-1301 (antiparkinsonian), colestimide (hypolipidaemic), colforsin daropate hydrochloride, denileukin diftitox others.
sci-hub.se 参考文章(117)
G. Emons, K.-D. Schulz, Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent results in cancer research. ,vol. 153, pp. 83- 94 ,(2000) , 10.1007/978-3-642-59587-5_7
Clarence Chant, Michael J Rybak, Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic Annals of Pharmacotherapy. ,vol. 29, pp. 1022- 1027 ,(1995) , 10.1177/106002809502901013
Cheryl M. Hayward, Mark J. Bamberger, Chapter 10. Emerging Opportunities in the Treatment of Atherosclerosis Annual Reports in Medicinal Chemistry. ,vol. 32, pp. 101- 110 ,(1997) , 10.1016/S0065-7743(08)61468-2
Christopher P.F. Redfern, Molecular Mechanisms of Retinoid Function Advances in Organ Biology. ,vol. 3, pp. 35- 77 ,(1997) , 10.1016/S1569-2590(08)60052-X
Xue-Min Cheng, Chapter 34. To Market, To Market - 1995 Annual Reports in Medicinal Chemistry. ,vol. 31, pp. 337- 355 ,(1996) , 10.1016/S0065-7743(08)60473-X
Bernard Gaudillière, Chapter 31. To Market, To Market - 1998 Annual Reports in Medicinal Chemistry. ,vol. 34, pp. 317- 338 ,(1999) , 10.1016/S0065-7743(08)60593-X
Paul Galatsis, Chapter 31. To Market, To Market - 1996 Annual Reports in Medicinal Chemistry. ,vol. 32, pp. 305- 326 ,(1997) , 10.1016/S0065-7743(08)61489-X
Karen L. Goa, Stuart Noble, Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs. ,vol. 57, pp. 439- 462 ,(1999) , 10.2165/00003495-199957030-00015
Dean Handley, The asthma-like pharmacology and toxicology of (S)-isomers of β agonists☆☆☆ The Journal of Allergy and Clinical Immunology. ,vol. 104, ,(1999) , 10.1016/S0091-6749(99)70276-9
Makoto HOSONO, [Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure]. Folia Pharmacologica Japonica. ,vol. 114, pp. 83- 88 ,(1999) , 10.1254/FPJ.114.83